A Phase 2/3 interventional study of sodium fusidate in Refractory Bone or Joint Infections, sponsored by Arrevus Inc.. Completed at 19 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-01-30.
Sponsored by Arrevus Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Osteomyelitis with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Osteomyelitis · United States.
Among the 37 studies in Osteomyelitis with a site in United States, this one is the 19th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2015, is the only one in phase 2/3, and was the 21st registered.
105 studies on the registry are indexed under Osteomyelitis; 30 are open to participants now.
Browse Osteomyelitis studies →5 of the 37 studies in Osteomyelitis with a site in United States are open now. Recruiting first, the newest first:
Biocomposites Ltd · Sites in United States
Ages 18+
Biocomposites Ltd · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 2 mo–18 yrs
BONESUPPORT AB · Sites in United States
Ages 18+
Methodist Health System · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Osteomyelitis studies recruiting now, 14 (61%) set no upper age limit and 7 (30%) stop at 75 or younger; 6 take children under 18; none take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 3 · Phase 4 6
First in 2002; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 74 across 60 interventional studies indexed under Osteomyelitis.
Median enrollment 41 across the 28 interventional studies, 70 across the 9 observational. Of the 27 that completed or were terminated, 12 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 37 have an industry lead sponsor. The 10 most frequent:
Arrevus Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Arrevus Inc. has 1 study filed under Osteomyelitis — fewer than ten, so there is no comparison to draw.
4 of the studies in Osteomyelitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00194298University of PennsylvaniaFDG-PET Imaging in Complicated Diabetic Foot | 2027-02 |
| NCT06982105Indiana UniversityTrimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections | 2027-06 |
| NCT06283979Biocomposites LtdA Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers. | 2027-08-01 |
| NCT07270380Biocomposites LtdAntibiotic Device for Osteomyelitis of the Extremities Pivotal Trial - Genex With Gentamicin. | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 37 studies in Osteomyelitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and effectiveness of oral sodium fusidate (CEM-102) as chronic antibiotic for the treatment of bone or joint infections.
Prospective, open-label, non-randomized, single-arm trial to evaluate the safety and effectiveness of CEM-102 for chronic antibiotic suppressive therapy of bone or joint infections. Subjects enrolling in this study must have a refractory staphylococcal bone or joint infection that requires suppressive antibiotic therapy (e.g. having an infection that cannot be managed by complete removal of the infected bone or foreign material, a refractory infection not responding to previous treatment, or not being a candidate for long-term intravenous antibiotic therapy).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy: * 6 months of treatment; or * 24 months of treatment (if continued on chronic suppressive therapy)
Drug: sodium fusidate
Also known as: CEM-102, fusidic acid
Clinical Success at 6 Months
Number of participants in the intent to treat (ITT) analysis set who meet all the criteria for clinical success at the 6-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
Time frame: 6 months after start of treatment
Safety and Tolerability
Number of participants with TEAEs, SAEs, deaths, and discontinuations due to AEs. Treatment-emergent adverse events, defined as events with a start date on or after the initiation of study drug through 28 days after the last dose of study drug, are reported.
Time frame: Entire study period - up to 24 months
Clinical Success at 9 Months
Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 9-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
Time frame: 9 months after start of treatment
Clinical Success at 12 Months
Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 12-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
Time frame: 12 months after start of treatment
Clinical Success at 15 Months
Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 15-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
Time frame: 15 months after start of treatment
Clinical Success at 18 Months
Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 18-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
Time frame: 18 months after start of treatment
Clinical Success at 21 Months
Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 21-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
Time frame: 21 months after start of treatment
Clinical Success at 24 Months
Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 24-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
Time frame: 24 months after start of treatment
| Milestone | CEM-102 (Sodium Fusidate) |
|---|---|
| Started | 30 |
| Completed | 9 |
| Not completed | 21 |
Number of participants in the intent to treat (ITT) analysis set who meet all the criteria for clinical success at the 6-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
| Participants | CEM-102 (Sodium Fusidate) |
|---|---|
| Clinical Success | 18 |
| Clinical Failure | 9 |
| Indeterminate | 3 |
Number of participants with TEAEs, SAEs, deaths, and discontinuations due to AEs. Treatment-emergent adverse events, defined as events with a start date on or after the initiation of study drug through 28 days after the last dose of study drug, are reported.
| Participants | CEM-102 (Sodium Fusidate) |
|---|---|
| Treatment Emergent AE (TEAE) | 29 |
| Severe TEAE | 12 |
| TEAE Related to Study Drug | 7 |
| TEAE Leading to Study Discontinuation | 9 |
| TEAE Leading to Study Drug Discontinuation | 12 |
| TE Serious Adverse Event (SAE) | 15 |
| TE SAE with outcome of death | 0 |
| TE SAE Related to Study Drug | 0 |
| TE SAE Leading to Study Discontinuation | 7 |
| TE SAE Leading to Study Drug Discontinuation | 9 |
Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 9-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
| Participants | CEM-102 (Sodium Fusidate) |
|---|---|
| Clinical Success | 15 |
| Clinical Failure | 11 |
| Indeterminate | 4 |
Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 12-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
| Participants | CEM-102 (Sodium Fusidate) |
|---|---|
| Clinical Success | 10 |
| Clinical Failure | 15 |
| Indeterminate | 5 |
Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 15-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
| Participants | CEM-102 (Sodium Fusidate) |
|---|---|
| Clinical Success | 8 |
| Clinical Failure | 17 |
| Indeterminate | 5 |
Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 18-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
| Participants | CEM-102 (Sodium Fusidate) |
|---|---|
| Clinical Success | 8 |
| Clinical Failure | 16 |
| Indeterminate | 6 |
Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 21-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
| Participants | CEM-102 (Sodium Fusidate) |
|---|---|
| Clinical Success | 6 |
| Clinical Failure | 17 |
| Indeterminate | 7 |
Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 24-Month Visit. Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia
| Participants | CEM-102 (Sodium Fusidate) |
|---|---|
| Clinical Success | 7 |
| Clinical Failure | 17 |
| Indeterminate | 6 |
Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CEM-102 (Sodium Fusidate) | 0/30 (0%) | 15/30 (50%) | 27/30 (90%) |
| Event | CEM-102 (Sodium Fusidate) |
|---|---|
| Device related infectionInfections and infestations | 4/30 |
| Cardiac failure congestiveCardiac disorders | 3/30 |
| Atrial fibrillationCardiac disorders | 2/30 |
| SyncopeNervous system disorders | 2/30 |
| BradycardiaCardiac disorders | 1/30 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/30 |
| Arthritis infectiveInfections and infestations | 1/30 |
| DiverticulitisInfections and infestations | 1/30 |
| PneumoniaInfections and infestations | 1/30 |
| PyelonephritisInfections and infestations | 1/30 |
| Event | CEM-102 (Sodium Fusidate) |
|---|---|
| Urinary tract infectionInfections and infestations | 9/30 |
| AnaemiaBlood and lymphatic system disorders | 4/30 |
| NauseaGastrointestinal disorders | 4/30 |
| Oedema peripheralGeneral disorders | 4/30 |
| Peripheral swellingGeneral disorders | 4/30 |
| PyrexiaGeneral disorders | 4/30 |
| DyspepsiaGastrointestinal disorders | 3/30 |
| HypokalemiaMetabolism and nutrition disorders | 3/30 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/30 |
| Vision blurredEye disorders | 2/30 |
Intent-to-Treat (ITT) Population included all subjects who provided informed consent, met all eligibility criteria, and were enrolled in the study.
| Age, Continuous(years) | CEM-102 (Sodium Fusidate) |
|---|---|
| Mean | 61 ± 13.4 |
| Sex: Female, Male(Participants) | CEM-102 (Sodium Fusidate) |
|---|---|
| Female | 10 |
| Male | 20 |
| Ethnicity (NIH/OMB)(Participants) | CEM-102 (Sodium Fusidate) |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 28 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | CEM-102 (Sodium Fusidate) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 27 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | CEM-102 (Sodium Fusidate) |
|---|---|
| United States | 30 |
| Height(cm) | CEM-102 (Sodium Fusidate) |
|---|---|
| Mean | 174.5 ± 11.54 |
| Weight(kg) | CEM-102 (Sodium Fusidate) |
|---|---|
| Mean | 87.4 ± 22.12 |
| BMI(kg/m2) | CEM-102 (Sodium Fusidate) |
|---|---|
| Mean | 28.7 ± 6.79 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Dec 2015, a primary completion of Oct 2017 and a completion of Feb 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2020, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fusidic Acid
Arrevus Inc.